© Globe Newswire
08.12.2025
HITC
LISTED
OTC
SafeSpace Global (SSGC) Announces Strategic Partnership With 911inform to Transform School Safety Across America
News Preview
Knoxville, TN, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to partner with 911inform, the nation’s most advanced emergency response and building intelligence platform protecting more than 13,000 facilities nationwide....
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
NEO
LISTED
NASDAQ
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting,...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company’s ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants wi...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
08.12.2025
TRUL
LISTED
CSE
Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Dec. 8, 2025 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has completed the redemption of all US$368,000,000 principal amount of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89788CAD6 / I...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
08.12.2025
TRUL
LISTED
CSE
Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has completed the redemption of all US$368,000,000 principal amount of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89788C...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
RMD
LISTED
NYSE
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
News Preview
Resmed received FDA Clearance for Personalized Therapy Comfort Settings, to be marketed as Smart Comfort....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
SANA
LISTED
NASDAQ
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
News Preview
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology ...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
NPCE
LISTED
NASDAQ
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
News Preview
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive therapy for the tr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
BRKR
LISTED
NASDAQ
Bruker Announces the Addition of Diagnostics Industry Leader Jack Phillips to its Board of Directors as of January 2026
News Preview
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experience in the diagnostics industry.
This press release features multimedia. View...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
CON
LISTED
NASDAQ
Concentra Expands to Corona, California
News Preview
Concentra® (NYSE: CON), the nation’s leader in occupational medicine, today announced the opening of a new medical center in Corona, California. The medical center, Concentra Corona, is conveniently located at 629 North Main Street, Unit C-3, Corona, California 92878.
“We’re excited to bring our medical services to Corona,” said Kathy Le, MD, sen...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
475830
LISTED
KOE
Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia
News Preview
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the presentation of preclinical data for ORM-1153 at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6 to 9, 2025, in Orlando, Florida. ORM-1153 i...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with B...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
08.12.2025
ONC
LISTED
NASDAQ
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
OMCL
LISTED
NASDAQ
Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management
News Preview
Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, today announced the launch of Omnicell Titan XT, a transformational, enterprise version of automated dispensing systems (ADS). Designed to unify proven automation and powerful intelligence, Titan XT will deliver an enhance...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
STAA
LISTED
NASDAQ
STAAR Surgical Announces Expiration of Go-Shop Period
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the previously announced go-shop period pursuant to STAAR’s amended merger agreement with Alcon Inc. (SIX/NYSE: ALC). The go-shop period expired at 11:59 p.m...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
News Preview
Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by downregulating expression of multiple genes associated with MDSC induced immunosuppression Data presented in the Company's poster demonstr...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
News Preview
Preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory (r/r) B-ALL patients was presented at ASH 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
IAN
LISTED
CSE
iAnthus Continues Expansion in Florida with the Opening of GrowHealthy’s 25th Dispensary in St. Petersburg
News Preview
iAnthus Continues Expansion in Florida with the Opening of GrowHealthy’s 25th Dispensary in St. Petersburg...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
IRMD
LISTED
NASDAQ
IRADIMED Announces Special Cash Dividend of $0.50 Per Share
News Preview
ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ERNA
LISTED
NASDAQ
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
News Preview
Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic malignancies Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the pote...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer’s disease, a progressive neurodegenerative disease characteriz...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GERN
LISTED
NASDAQ
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
News Preview
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
WELL
LISTED
TSX
WELL Subsidiary WELLSTAR Technologies Closes $62M Financing to Support Its Pre-Spinout Growth Strategy
News Preview
Not for distribution to U.S. news wire services or dissemination in the United States
WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (“WELL”), a digital healthcare company focused on improving health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its majorit...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in dri...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
MRK
LISTED
NYSE
Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program
News Preview
KIRKLAND, QC, Dec. 8, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eli...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driv...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving gro...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
UCB
LISTED
EURONEXT
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
News Preview
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1Holistic Improvement: two of the three key secondary endpoints showed significantly greater number of patients demonstrated ≥50% reduction in CMSF from basel...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
KPTI
LISTED
NASDAQ
Karyopharm to Participate in Baird's Biotech Discovery Series
News Preview
NEWTON, Mass., Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday,...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ALSAF
LISTED
EURONEXT
SAFE - Mise à disposition du Rapport Financier Semestriel 2025
News Preview
Mise à disposition du Rapport Financier Semestriel 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
NRIX
LISTED
NASDAQ
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
News Preview
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
PRAX
LISTED
NASDAQ
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
News Preview
Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p ≤ 0.002)...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
FATE
LISTED
NASDAQ
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
News Preview
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GDTC
LISTED
NASDAQ
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
News Preview
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, inc...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GPCR
LISTED
NASDAQ
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
News Preview
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
SABS
LISTED
NASDAQ
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
News Preview
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
FDMT
LISTED
NASDAQ
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will pr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
45680
LISTED
XJPX
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
News Preview
Daiichi Sankyo (TSE: 4568) will present new breast cancer clinical research across its DXd antibody drug conjugate (ADC) portfolio from more than 30 abstracts at the 2025 San Antonio Breast Cancer Symposium (#SABCS25), which include four rapid fire mini-oral sessions and other presentations from five landmark trials of ENHERTU® (trastuzumab deruxt...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified a...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
NWRN
LISTED
SIX
Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
News Preview
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the initiation of its ENIGMA-TRS 2 Phase III clinical study in the US, following approvals from the US Food and Drug Adm...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
PEPG
LISTED
NASDAQ
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than t...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
RXRX
LISTED
NASDAQ
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
News Preview
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP)....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
WVE
LISTED
NASDAQ
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
News Preview
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo g...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
COGT
LISTED
NASDAQ
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
News Preview
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggreg...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ABEO
LISTED
NASDAQ
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
News Preview
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Z...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
PCVX
LISTED
NASDAQ
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
News Preview
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
OCUL
LISTED
NASDAQ
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
News Preview
Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
AGIO
LISTED
NASDAQ
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
News Preview
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
CRDF
LISTED
NASDAQ
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
News Preview
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is tak...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
News Preview
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
OBIO
LISTED
NASDAQ
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
News Preview
NEW HOPE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced three presentations at the 2025 Innovation in Cardiology Intervention (“IC...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2025
HBFG
LISTED
CSE
Happy Belly Food Group Announces Executive Leadership Plan to Support Next Phase of Growth
News Preview
Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce executive management updates to support its 2026 growth plan as the Company advances its objective of doubling the size of its...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
News Preview
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose -...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
ONCO
LISTED
NEO
Onco-Innovations beauftragt Investmentbank mit der Prüfung einer Nasdaq-Notierung und eines möglichen gleichzeitigen Emissionsangebots
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es eine US-Investmentbank als Kapitalmarktberater beauftragt hat, um mit seiner Absicht eine mögliche zusätzliche Notierung (Cross-Listing) an der “Nasdaq Stock Market LLC” (Nasdaq oder die Börse) anzustreben und parallel eine mögl......
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
MNOV
LISTED
NASDAQ
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
News Preview
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amy...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
SNWV
LISTED
NASDAQ
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
News Preview
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
MDCE
LISTED
OTC
Medical Care Technologies (OTC Pink:MDCE) Positions Itself in the Multi-Billion Dollar AI Dermatology Market With Google-Backed Melanoma Detection Technology
News Preview
MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce a major technology advancement in the development of its soon-to-launch AI wound and skin monitoring platform. The Company has strategically aligned with Derm Foundation, a Google-backed pretrained dermatology imaging model, e...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
VIRP
LISTED
EURONEXT
Virbac : Declaration of the number of shares and voting rights 11/2025
News Preview
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
CASI
LISTED
NASDAQ
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
News Preview
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced data presented from its Phas...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
RGNT
LISTED
XASE
Regentis Biomaterials Commences Trading on NYSE: Set to Transform Cartilage Repair Market with Off-the-Shelf Regenerative Product
News Preview
Lead product GelrinC®, a hydrogel synchronized erosion and resorbable implant, the only restorative product for knee cartilage repair, is a breakthrough effective and economical procedure to address a large unmet needGelrinC is approved for knee cartilage repair in the European Union and is currently at midpoint in a pivotal FDA trial for the...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
